MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.45
+0.06
+0.64%
After Hours: 9.41 -0.04 -0.42% 17:14 05/17 EDT
OPEN
9.30
PREV CLOSE
9.39
HIGH
9.53
LOW
9.24
VOLUME
20.69K
TURNOVER
--
52 WEEK HIGH
29.40
52 WEEK LOW
4.490
MARKET CAP
172.99M
P/E (TTM)
-10.9641
1D
5D
1M
3M
1Y
5Y
MARA, BNTX, OCGN and ATOS among notable premarket gainers
Brooklyn ImmunoTherapeutics (BTX) +38%.Regional Health Properties (RHE) +21%.Gaucho Group Holdings (VINO) +15%.Ashford Hospitality Trust (AHT) +15%.Ocugen (OCGN) +13% as COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2,...
Seekingalpha · 05/03 12:26
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/03 12:08
22 Stocks Moving in Monday's Pre-Market Session
Gainers
Benzinga · 05/03 11:02
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.
Benzinga · 04/30 09:22
FB, QCOM, NOK and VER among premarket gainers
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Plur...
Seekingalpha · 04/29 12:26
Analysts Offer Insights on Healthcare Companies: Enlivex Therapeutics (ENLV), Collplant Holdings (CLGN) and Satsuma Pharmaceuticals (STSA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex Therapeutics (ENLV), Collplant Holdings (CLGN) and
SmarterAnalyst · 03/29 10:25
Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings
Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a 
Benzinga · 03/22 16:54
Enlivex enters Allocetra research collaboration with Yale Cancer Center
Enlivex Therapeutics (ENLV) announces a research collaboration with Yale Cancer Center for the assessment of the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.Allocetra is a macrophage-reprogramming
Seekingalpha · 03/22 12:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENLV. Analyze the recent business situations of Enlivex Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENLV stock price target is 33.00 with a high estimate of 33.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 950.76K
% Owned: 5.19%
Shares Outstanding: 18.31M
TypeInstitutionsShares
Increased
4
59.71K
New
6
504.67K
Decreased
1
11.53K
Sold Out
1
434
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Director
Shai Novik
Chief Executive Officer
Oren Hershkovitz
Founder/Chief Scientific Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Other
Odelia Ben-Shitrit
Director
Michel Habib
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Hyun Gyu Lee
Director
Sangwoo Lee
Director
Brian Schwartz
Independent Director
Gili Hart
Independent Director
Abraham Havron
No Data
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.